CRS is particularly associated with treatments designed to harness the body's immune system to attack cancer cells. When therapies like CAR T-cell therapy are administered, they activate a large number of immune cells that release cytokines such as interleukin-6 (IL-6), interleukin-2 (IL-2), and interferon-gamma (IFN-γ). These cytokines can lead to a hyperactive immune response, causing widespread inflammation and tissue damage.
